MedGenome Launches CNS Tumor Methylation Classifier Test in India

The test is designed to complement traditional histology and assist clinicians in making more precise treatment decisions.

MedGenome, a genomic diagnostics and research services company, has launched the CNS tumor Methylation Classifier Test (MCT) in India, enabling the classification of over 90 types of brain and central nervous system (CNS) tumors. The test is designed to complement traditional histology and assist clinicians in making more precise treatment decisions.

The MCT uses DNA methylation profiling to detect molecular changes in tumor samples, creating a molecular signature that is compared against a global reference database to determine the tumor subtype. This approach is particularly useful for rare or complex cases where conventional pathology may not provide clear results.

According to the company, the test aligns with the World Health Organization’s 2021 guidelines for CNS tumor classification. Results are provided within 21 days and include WHO grade assignment, genome-wide copy number profiling, and identification of key gene alterations. This information offers clinicians a detailed view of tumor biology, supporting more informed diagnostic and treatment decisions.

The test was announced during a precision oncology symposium in Mumbai, co-hosted by MedGenome and Illumina. The event was attended by oncologists, neuro-oncologists, pathologists, researchers, and doctoral students, highlighting the clinical relevance of molecular tumor profiling in modern oncology.

By integrating genomic data with traditional histology, MedGenome aims to enhance diagnostic accuracy and provide actionable molecular insights for CNS tumors. The MCT represents a step toward more personalized approaches in neuro-oncology, enabling healthcare providers to better predict tumor behavior and treatment response.

Stay tuned for more such updates on Digital Health News